Patents by Inventor Bernt Borretzen

Bernt Borretzen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6762175
    Abstract: The properties of biologically active compounds, for example drugs and agrochemicals, which contain in their molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, carboxylic acid and carboxylic acid ester groups are modified by replacing one or more of these functional groups by a lipophilic group selected from those of the formula: RCOO—, RCONH—, RCOS—, RCH2O—, RCH2NH—, —COOCH2R, —CONHCH2R and —SCH2R, wherein R is a lipophilic moiety selected from cis-8-heptadecenyl, trans-8-heptadecenyl, cis-10-nonadecenyl and trans-10-nonadecenyl.
    Type: Grant
    Filed: April 5, 2002
    Date of Patent: July 13, 2004
    Assignee: Norsk Hydro ASA
    Inventors: Finn Myhren, Bernt Børretzen, Are Dalen, Marit Liland Sandvold
  • Publication number: 20040063677
    Abstract: The properties of biologically active compounds, for example drugs and agrochemicals, which contain in their molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, carboxylic acid and carboxylic acid ester groups are modified by replacing one or more of these functional groups by a lipophilic group selected from those of the formula: RCOO—, RCONH—, RCOS—, RCH2O—, RCH2NH—, —COOCH2R, —CONHCH2R and —SCH2R, wherein R is a lipophilic moiety selected from cis-8-heptadecenyl, trans-8-heptadecenyl, cis-10-nonadecenyl and trans-10-nonadecenyl.
    Type: Application
    Filed: September 16, 2003
    Publication date: April 1, 2004
    Applicant: Norsk Hydro ASA
    Inventors: Finn Myhren, Bernt Borretzen, Are Dalen, Marit Liland Sandvold
  • Publication number: 20030153544
    Abstract: The properties of biologically active compounds, for example drugs and agrochemicals, which contain in their molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, carboxylic acid and carboxylic acid ester groups are modified by replacing one or more of these functional groups by a lipophilic group selected from those of the formula: RCOO—, RCONH—, RCOS—, RCH 2 O—, RCH 2 NH—, —COOCH 2 R, —CONHCH 2 R and —SCH 2 R, wherein R is a lipophilic moiety selected from cis-8-heptadecenyl, trans-8-heptadecenyl, cis-10-nonadecenyl and trans-10-nonadecenyl.
    Type: Application
    Filed: April 5, 2002
    Publication date: August 14, 2003
    Inventors: Finn Myhren, Bernt Borretzen, Are Dalen, Marit Liland Sandvold
  • Patent number: 6548486
    Abstract: New compounds of the general formula (I): Nu-O-Fa, wherein O represents an oxygen, Nu is a nucleoside or nucleoside analogue, and Fa is an acyl group of a mono-unsaturated C18 or 20 fatty acid. The invention also concerns anti viral pharmaceutical and veterinary compositions comprising a compound of formula (I) alone in a combination with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: September 21, 1994
    Date of Patent: April 15, 2003
    Assignee: Norsk Hydro a.s.
    Inventors: Are Dalen, Finn Myhren, Bernt Børretzen, Kjell Torgeir Stokke
  • Patent number: 6384019
    Abstract: The invention provides Gemcitabine esters or amides in which the 3′- and/or 5′-OH group and/or the N4-amino group is derivatised with a C18- and/or C20-saturated or mono-unsaturated acyl group, preferably an acyl group selected from oleoyl, elaidoyl, cis-eicosenoyl and trans-eicosenoyl. The Gemcitabine esters and amides are useful as anti-cancer and anti-viral agents.
    Type: Grant
    Filed: September 15, 1999
    Date of Patent: May 7, 2002
    Assignee: Norsk Hydro ASA
    Inventors: Finn Myhren, Bernt Børretzen, Are Dalen, Marit Liland Sandvold
  • Publication number: 20020042391
    Abstract: The invention provides Gemcitabine esters or amides in which the 3′- and/or 5′-OH group and/or the N4-amino group is derivatised with a C18- and/or C20-saturated or mono-unsaturated acyl group, preferably an acyl group selected from oleoyl, elaidoyl, cis-eicosenioyl and trans-eicosenoyl. The Gemcitabine esters and amides are useful as anti-cancer and anti-viral agents.
    Type: Application
    Filed: September 15, 1999
    Publication date: April 11, 2002
    Inventors: FINN MYHREN, BERNT BORRETZEN, ARE DALEN, MARIT LILAND SANDVOLD
  • Patent number: 6335322
    Abstract: wherein R is selected from the group consisting of elaidoyl, cis-eicosenoyl and trans-eicosenoyl; and pharmaceutical compositions comprising the Ara-C derivative.
    Type: Grant
    Filed: November 9, 1999
    Date of Patent: January 1, 2002
    Assignee: Norsk Hydro ASA
    Inventors: Finn Myhren, Bernt Børretzen, Are Dalen, Kjell Torgeir Stokke
  • Patent number: 6316425
    Abstract: This invention relates to new nucleoside derivatives of formula (I); wherein R1 and R2 are independently selected from hydrogen, elaidoyl, oleoyl, stearoyl, eicosenoyl (cis or trans) and eicosanoyl, with the provisos that R1 and R2 cannot both be hydrogen, oleoyl or stearoyl, R1 cannot be hydrogen when R2 is oleoyl or stearoyl, and R2 cannot be hydrogen when R1 is elaidoyl, oleoyl or stearoyl. Further, the invention relates to the use of the nucleoside derivatives of formula (I) wherein R1 and R2 are independently selected from hydrogen, and C18- and C20-saturated and mono-unsaturated acyl groups, with the provisos that R1 and R2 cannot both be hydrogen, in the manufacture of a pharmaceutical preparation for the treatment of tumours.
    Type: Grant
    Filed: May 26, 1998
    Date of Patent: November 13, 2001
    Assignee: Norsk Hydro ASA
    Inventors: Finn Myhren, Bernt Børretzen, Are Dalen, Kjell Torgeir Stokke
  • Publication number: 20010006962
    Abstract: The properties of biologically active compounds, for example drugs and agrochemicals, which contain in their molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, carboxylic acid and carboxylic acid ester groups are modified by replacing one or more of these functional groups by a lipophilic group selected from those of the formula: RCOO—, RCONH—, RCOS—, RCH2O—, RCH2NH—, —COOCH2R, —CONHCH2R and —SCH2R, wherein R is a lipophilic moiety selected from cis-8-heptadecenyl, trans-8-heptadecenyl, cis-10-nonadecenyl and trans-10-nonadecenyl.
    Type: Application
    Filed: September 27, 1999
    Publication date: July 5, 2001
    Inventors: FINN MYHREN, BERNT BORRETZEN, ARE DALEN, MARIT LILAND SANDVOLD
  • Patent number: 5502077
    Abstract: Fatty acid composition comprising at least 80% by weight of omega-3-fatty acids, salts or derivatives thereof, wherein (all-Z)-5,8,11,14,17-eicosapentaenoic acid (EPA) and (all-Z)-4,7,10,13,16,19-docosahexaenoic acid comprises at least 75% by weight of the total fatty acids. The compositions can be used for the treatment or prophylaxis of multiple risk factors for cardiovascular diseases.
    Type: Grant
    Filed: June 23, 1992
    Date of Patent: March 26, 1996
    Assignee: Norsk Hydro A.S.
    Inventors: Harald Breivik, Bernt Borretzen, Knut H. Dahl, Hans E. Krokan, Kaare H. Bonaa
  • Patent number: 5393741
    Abstract: New compounds having the general formula I ##STR1## wherein Y may be H or D; and A is H, D, alkyl with 1-4 C-atoms, halogen, nitro, amino, monoalkyl amino or dialkyl amino wherein the alkyl groups have 1-4 C atoms or OR wherein R is H or alkyl of 1-4 C-atoms;X.sub.1 and X.sub.2 may together with the carbon atom to which they are bound form a cyclic acetal, thioacetal, dithiane, aminal, oxazolidine or thiazolidine;or pharmaceutically acceptable salts thereof.The compounds are useful as anti-carcinoma agents.
    Type: Grant
    Filed: November 27, 1991
    Date of Patent: February 28, 1995
    Assignee: Norsk Hydro a.s.
    Inventors: Erik O. Pettersen, Rolf O. Larsen, Bernt Borretzen, John M. Dornish, Reidar Oftebro
  • Patent number: 5324859
    Abstract: New compounds of formula I: ##STR1## wherein Y may be CN or ##STR2## wherein A may be H, D, alkyl with 1-4 carbon atoms, OR wherein R is H or alkyl with 1-4 carbon atoms, or --NR.sub.1 R.sub.2 or --CR.sub.1 R.sub.2 R.sub.3 wherein R.sub.1, R.sub.2 and R.sub.3 are the same or different and are H or alkyl with 1-4 carbon atoms;Z is H, D, Y or alkyl with 1-4 C-atoms, halogen, nitro, amino, monoalkyl amino or dialkyl amino wherein the alkyl groups have 1-4 C atoms, or --OR wherein R may be H or alkyl with 1-4 C-atoms or --CR.sub.4, R.sub.5 R.sub.6 wherein R.sub.4, R.sub.5 and R.sub.6 may be the same or different and may be H or F;and pharmaceutically acceptable salts thereof,are useful as anti-cancer agents or as intermediates for preparing anti-cancer agents.
    Type: Grant
    Filed: January 19, 1993
    Date of Patent: June 28, 1994
    Assignee: Norsk Hydro A.S.
    Inventors: Erik O. Pettersen, Rolf O. Larsen, John M. Dornish, Bernt Borretzen, Reidar Oftebro, Thomas Ramdahl
  • Patent number: 5149820
    Abstract: Deuterated aromatic aldehydes of the formula: ##STR1## where Ar is substituted phenyl, and derivatives thereof represented by the formula: ##STR2## where Ar is substituted or unsubstituted phenyl, and X.sub.1 and X.sub.2 are substituted hetero atoms or together with the carbon to which they are attached form a heterocycle. These compounds are useful as anticancer and analgesic agents.
    Type: Grant
    Filed: August 21, 1989
    Date of Patent: September 22, 1992
    Assignee: Norsk Hydro A.S.
    Inventors: Bernt Borretzen, Rolf O. Larsen, Erik O. Pettersen, John M. Dornish, Reider Oftebro
  • Patent number: 5135948
    Abstract: The use of L-ascorbic acid, or a pharmaceutically acceptable salt thereof, in combination with 5,6-O-benzylidene-L-ascorbic acid, or 5,6-O-benzylidene-L-ascorbic acid deuterated at least at the 1-position of the aldehyde group of the benzylidene moiety, or a pharmaceutically acceptable salt of such acids, results in a synergistically enhanced cytotoxicity on human carcinoma cells.
    Type: Grant
    Filed: September 12, 1990
    Date of Patent: August 4, 1992
    Assignee: Norsk Hydro a.s.
    Inventors: Bernt Borretzen, Rolf O. Larsen, John M. Dornish, Reidar Oftebro, Erik O. Pettersen
  • Patent number: 5130145
    Abstract: Anti-cancer platinum complexes such as cisplatin exhibit a synergistically higher level of anti-tumour activity when administered substantially simultaneously either with L-ascorbic acid, or with 5,6-O-benzylidene-L-ascorbic acid or deuterated forms thereof.
    Type: Grant
    Filed: June 20, 1991
    Date of Patent: July 14, 1992
    Assignee: Norsk Hydro A.S.
    Inventors: Reidar Oftebro, Erik O. Pettersen, John M. Dornish, Bernt Borretzen, Rolf O. Larsen
  • Patent number: 5049396
    Abstract: Anti-cancer platinum complexes such as cisplatin exhibit a synergistically high level of anti-tumor activity when administered substantially simultaneously either with L-ascorbic acid, or with 5,6-O-benzylidene-L-ascorbic acid or deuterated forms thereof.
    Type: Grant
    Filed: March 27, 1989
    Date of Patent: September 17, 1991
    Assignee: Norsk Hydro A.S.
    Inventors: Reidar Oftebro, Erik O. Pettersen, John M. Dornish, Bernt Borretzen, Rolf O. Larsen
  • Patent number: 5032610
    Abstract: The use of L-ascorbic acid, or a pharmaceutically acceptable salt thereof, in combination with 5,6-O-benzylidene-L-ascorbic acid, or 5,6-O-benzylidene-L-ascorbic acid deuterated at least at the 1-position of the aldehyde group of the benzylidene moiety, or a pharmaceutically acceptable salt of such acids, results in a synergistically enhanced cytotoxicity on human carcinoma cells.
    Type: Grant
    Filed: November 21, 1988
    Date of Patent: July 16, 1991
    Assignee: Norsk Hydro AS
    Inventors: Bernt Borretzen, Rolf O. Larsen, John M. Dornish, Reidar Oftebro, Erick O. Pettersen
  • Patent number: 4874780
    Abstract: Deuterated aromatic aldehydes of the formula: ##STR1## where Ar is substituted phenyl, and derivatives thereof represented by the formula: ##STR2## where Ar is substituted or unsubstituted phenyl, and X.sub.1 and X.sub.2 are substituted hetero atoms or together with the carbon to which they are attached from a heterocycle. These compounds are useful as anticancer agents.
    Type: Grant
    Filed: March 11, 1987
    Date of Patent: October 17, 1989
    Assignee: Norsk Hydro a.s.
    Inventors: Bernt Borretzen, Rolf O. Larsen, Erik O. Pettersen, John M. Dornish, Rolf Oftebro